Pacific Edge underpins its products with a strong portfolio of patents in prosecution. The company has two issued patents, in New Zealand and Singapore, for its bladder cancer detection product Cxbladder®.
In addition, Pacific Edge has filed provisional patents and PCT applications for cancer specific biomarkers and their application as diagnostic and prognostic tools for each of the cancers of interest to us. Our next product, Cxcolorectal®, will be protected by an issued patent in New Zealand.
The company also has issued patents in NZ, the USA and Australia covering its SIFTware software platform technology. This technology enables the analysis of complex fields of data and is used in the company’s biomarker and assay development programmes. The company has filed provisional patent applications on extended applications of its analytical tools in specific applications related to patient risk assessment and use of prognostics.
Pacific Edge utilises experienced patent attorneys in both New Zealand and the US to contribute to the development, filing and prosecution of patents and to our intellectual property strategies.
Pacific Edge also has immediate and perpetual access to any cancer intellectual property emerging from the University of Otago’s Cancer Genetics Laboratory. This relationship has been in place from when Pacific Edge was formed in 2001. This represents a significant future asset.
|Bladder cancer||New Zealand, Singapore|
|Colorectal cancer||New Zealand|
|Gastric cancer||New Zealand|
|Adaptive learning system and method||New Zealand, USA, Australia|
|Melanoma cancer||New Zealand|